Mitsui Toatsu Chemicals, Incorporated

Mitsui Chemicals, Inc.

Michihiko Miyamoto

Tadahito Nobori

Nobuya Kawauchi

Joji Kamiya

Tsutomu Katakami

Masaaki Ishii

Haruki Mori

Tatsuro Yokoyama

Masahiro Ohta

Yasunori Yoshida

Hiroyuki Yamashita

Shoji Obuchi

Kenichi Goto

Koichi Ebihara

Kunio Okumura

Daisuke Ura

Yukiko Mori

Kunio Sannohe

Toshiyuki Shimazaki

Kenji Kibayashi

Kouhei Yazawa

Kanji Yoshihara

Isao Yokoyama

Takanori Yutaka

Kan Ideda

Tatsuo Kaiho

A process, as a substitute for hydrolysis, for preparing a nitroguanidine derivative represented by the following formula (2): ##STR1## wherein A represents a substituted or unsubstituted aromatic or non-aromatic hydrocarbon ring, a substituted or unsubstituted aromatic or non-aromatic heterocycle, a hydrogen atom or a substituted or unsubstituted alkyl, alkenyl or alkynyl group; and R.sub.2 represents a hydrogen atom, a substituted or unsubstituted C.sub.1-6 alkyl, alkenyl or alkynyl group, which comprises reacting a compound represented by the following formula (1): ##STR2## wherein R.sub.1 represents a substituted or unsubstituted, linear or cyclic C.sub.1-10 alkyl group and A and R.sub.2 have the same meanings as defined above, with ammonia, a primary amine or a secondary amine, or a salt thereof.

Preparation process of nitroguanidine derivatives

The invention relates to a preparation process of aliphatic polyester, comprising using an ion exchange resin as a drying agent and after the dehydration polycondensation reaction, regenerating and drying the used ion exchange resin and repeatedly using said ion exchange resin in the next dehydration polycondensation reaction, in a process for preparing aliphatic polyester from one or more aliphatic compound (A) by heating in an organic solvent in the presence of a catalyst, distilling a generated water containing organic solvent out of the reaction system, treating the distilled organic solvent with a drying agent, and returning the treated solvent to the reaction system to progress a dehydration polycondensation reaction. The process of the invention enables one to steadily and efficiently prepare in industry an aliphatic polyester having an excellent color tone, high molecular weight and high quality.

Preparation process of aliphatic polyester

A preparation process of polyhydroxycarboxylic acid comprising conducting dehydration polycondensation of hydroxycarboxylic acid or an oligomer of the same in a reaction mixture containing said hydroxycarboxylic acid or the oligomer of the same and an organic solvent substantially in the absence of water to give polyhydroxycarboxylic acid having an weight average molecular weight of 50,000 or more, successively mixing the reaction mixture containing said polyhydroxycarboxylic acid with at least one binder selected from the group consisting of (1) polyisocyanate compound, (2) polybasic acid anhydride, (3) cyclic imino ester, (4) cyclic imino ether, (5) aromatic hydroxycarboxylic acid, (6) polyamino compound, (7) polyhydric alcohol, (8) epoxy compound, (9) polyfunctional aziridine compound, (10) lactam, (11) lactone, and (12) diethylene glycol bischloroforate, and reacting to obtain polyhydroxycarboxylic acid having a weight average molecular weight of 100,000 or more the polyhydroxycarboxylic acid which is obtained by the process has a weight average molecular weight of 100,000 or more, has satisfactory mechanical strength in the form of molded articles and is useful as a degradable polymer for substituting medical materials and general purpose resins.

Preparation process of polyhydroxycarboxylic acid

The invention relates to a novel compound which is represented by the formula (1) and has an excellent platelet aggregation inhibiting action based on fibrinogen antagonism. The platelet aggregation inhibitor containing the compound of the formula (1) as an effective ingredient are effective for prevention and curing of thrombosis and restenosis or reocclusion after percutaneous transluminal coronary angioplasty or percutaneous transluminal coronary recanalization.

Bicyclic compound and platelet aggregation inhibitor containing the same

Pyrimidinedione derivatives of the formula: ##STR1## wherein R.sup.1 and R.sup.2 is so linked with each other as to make an alkylene chain and thus form a heterocyclic structure, A, R.sup.3, R.sup.4, X.sup.1, X.sup.2 and X.sup.3 are substituents, respectively, and n is 2 or 3 have a basic backbone in which a phenyl group part and a pyrimidinedione part are linked by a structure comprising an alkyl chain and a heterocyclic ring having two nitrogen atoms. These compounds are useful for a medical treatment of cardiac arrhythmias.

Pyrimidinedione derivatives and antiarrhythmic agents containing same

A pyrimidinedione derivative compound has a basic backbone in which a phenyl group part and a pyrimidinedione part are linked by a linking structure comprising an alkyl chain containing two nitrogen atoms. This linking structure is represented by ##STR1## [wherein A is --(CH.sub.2).sub.n --, --CO-- or --O--(CH.sub.2).sub.m --; each of R.sup.1 and R.sup.2 is independently a hydrogen atom or a lower alkyl group which may be substituted by a hydroxyl group, or R.sup.1 and R.sup.2 may be so linked with each other as to make an alkylene chain and thus form a heterocyclic structure; R.sup.5 is a halogen atom, a hydroxyl group, a lower alkyloxycarbonyl group, a lower alkyloxy group which may be substituted by a lower alkyloxy group, or a lower alkyl group which may be substituted by a hydroxyl group, or R.sup.5 may be so linked with R.sup.1 as to make an alkylene chain and thus form a heterocyclic structure; n is 0, 1, 2 or 3 (when R.sup.5 is the hydroxyl group, n.noteq.0); m is 0, 1, 2 or 3; and k is 0, 1, 2 or 3 (however, a compound in which A is --O--(CH.sub.2).sub.m -- and R.sup.5 is the hydroxyl group is excluded from the pyrimidinedione derivative)]. The pyrimidinedione derivative and its acid addition salt are useful for a medical treatment of cardiac arrhythmias.

Pyrimidinedione derivatives and antiarrythmic agents containing the same

A pyrimidinedione derivative compound has a basic backbone in which a phenyl group part and a pyrimidinedione part are linked by a structure comprising an alkyl chain containing at least two nitrogen atoms. The pyrimidinedione derivative is useful for a medical treatment of cardiac arrhythmias.

Pyrimidinedione compounds, method of producing the same and

Growing community of inventors

Fukuoka-ken, Japan

Michihiko Miyamoto